Table 2 The diagnostic value of ten TAAbs in the test phase
From: A novel autoantibody signatures for enhanced clinical diagnosis of pancreatic ductal adenocarcinoma
TAAbs | NC | BPD | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
AUC (95%CI) | Sen (%) | Spe (%) | Acc (%) | P | AUC (95%CI) | Sen (%) | Spe (%) | Acc (%) | P | |
FUCA2 | 0.70(0.63–0.77) | 34.00 | 87.00 | 60.50 | < 0.001 | 0.60(0.51–0.68) | 28.00 | 86.25 | 53.89 | < 0.05 |
LTF | 0.62(0.54–0.70) | 36.00 | 86.00 | 61.00 | < 0.05 | 0.58(0.50–0.66) | 26.00 | 85.00 | 52.22 | 0.06 |
HEXB | 0.63(0.55–0.70) | 19.00 | 92.00 | 55.50 | < 0.05 | 0.56(0.47–0.65) | 9.00 | 95.00 | 47.22 | 0.164 |
OSCAR | 0.64(0.56–0.71) | 29.00 | 86.00 | 57.50 | < 0.001 | 0.61(0.53–0.69) | 22.00 | 91.25 | 52.78 | < 0.05 |
PSMD2 | 0.61(0.53–0.69) | 17.00 | 95.00 | 56.00 | < 0.05 | 0.67(0.59–0.75) | 26.00 | 86.25 | 52.78 | < 0.001 |
TXLNA | 0.76(0.70–0.83) | 50.00 | 89.00 | 69.50 | < 0.001 | 0.73(0.66–0.80) | 44.00 | 92.50 | 65.56 | < 0.001 |
SLAMF6 | 0.74(0.67–0.81) | 42.00 | 86.00 | 64.00 | < 0.001 | 0.72(0.64–0.79) | 39.00 | 88.75 | 61.11 | < 0.001 |
LILRB2 | 0.65(0.57–0.73) | 7.00 | 100.00 | 53.50 | < 0.001 | 0.52(0.43–0.61) | 17.00 | 87.50 | 48.33 | 0.652 |
TP53 | 0.62(0.54–0.70) | 14.00 | 100.00 | 57.00 | < 0.05 | 0.66(0.58–0.74) | 26.00 | 90.00 | 54.44 | < 0.001 |
IGFBP2 | 0.61(0.53–0.69) | 17.00 | 95.00 | 56.00 | < 0.05 | 0.67(0.59–0.75) | 26.00 | 86.25 | 52.78 | < 0.001 |